x
[contact-form-7 404 "Not Found"]

Tag: recent post

Alzheimer's

Sep2018

Artificial Intelligence enables first biomarker driven precision medicine therapy against Alzheimer

Tersan Pharmaceuticals Ltd helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase 2a clinical trial. Tersan’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73. Professor Harald Hampel, M.D., Ph.D., presenting results at the AAIC […]

Read More
Cancer

Sep2018

Recombio and Tersan Pharmaceuticals Ltd Identify Lung Cancer Patients Most Benefiting from Racotumomab Vaccine Therapy

Tersan has applied its advanced Artificial Intelligence platform KEM® and identified best responders to Racotumomab based on patients’ immune profile. Racotumab is a therapeutic vaccine developed by Recombio against non-small cell lung cancer (NSCLC), the most frequent type of lung cancers. Paris, Cambridge (MA) and Madrid– September 6, 2018 – Tersan Pharmaceuticals Ltd (Paris, France and […]

Read More
Alzheimer's

Aug2018

Applying the cancer playbook to find treatment for Alzheimer’s disease

Applying the cancer playbook to find treatment for Alzheimer’s disease: see how Tersan’s KEM Artificial Intelligence platform is helping Anavex Life Sciences develop the first targeted therapy against Alzheimer’s disease.   “NEW YORK – July 25, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics […]

Read More